Advertisement
Advertisement
ADIL
Adial Pharmaceuticals, Inc
4.21
USDSponsored
+0.23
+5.78%
Aug 10, 15:59 UTC -4
Closed
After-Market
4.08
-0.13
-2.99%
ADIL Earnings Reports
Positive Surprise Ratio
ADIL beat 14 of 27 last estimates.
52%
Next Report
Tomorrow
Date of Next Report
Aug 11, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$1.03
Implied change from Q1 26 (Revenue/ EPS)
--
/-30.41%
Implied change from Q2 25 (Revenue/ EPS)
--
/-77.11%
Adial Pharmaceuticals, Inc earnings per share and revenue
On May 08, 2026, ADIL reported earnings of -1.48 USD per share (EPS) for Q1 26, beating the estimate of -2.78 USD, resulting in a 46.85% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.70% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -1.03 USD, with revenue projected to reach -- USD, implying an decrease of -30.41% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bionano Genomics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.69
Actual
-$0.64
Surprise
+8.40%
Biohaven Ltd.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.74
Actual
-$0.91
Surprise
-21.67%
Alamar Biosciences, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.22
Surprise
+33.83%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Rocket Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
$0.24
Actual
-$0.15
Surprise
-160.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
Orchestra BioMed Holdings, Inc. Ordinary Shares
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.38
Surprise
+4.95%
Nkarta, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.54
Surprise
-40.81%
FAQ
What were Adial Pharmaceuticals, Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Adial Pharmaceuticals, Inc reported EPS of -$1.48, beating estimates by 46.85%, and revenue of --, 0% as expectations.
How did the market react to Adial Pharmaceuticals, Inc's Q1 2026 earnings?
The stock price moved up 0.7%, changed from $1.43 before the earnings release to $1.44 the day after.
When is Adial Pharmaceuticals, Inc expected to report next?
The next earning report is scheduled for Aug 11, 2026.
What are the forecasts for Adial Pharmaceuticals, Inc's next earnings report?
Based on 4
analysts, Adial Pharmaceuticals, Inc is expected to report EPS of -$1.03 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement